SBPH News and Press, Spring Bank From 05/07/20

Spring Bank Pharma (NASDAQ: SBPH ): Q1 GAAP EPS of -$0.49 misses by $0.29 . More news on: Spring Bank Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq ® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists portfolio as potential therapeutics and/or vaccine a...

Siemens Healthineers ( OTCPK:SIEGY ) announces the availability of its molecular test for SARS-CoV-2. Shipments in process in Europe. More news on: Siemens Aktiengesellschaft, Geron Corporation, Galectin Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Pursuing collaborations to develop internal compounds for potential treatment of COVID-19 Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohort Clinical abstracts for IV SB 11285...

VivoPower International PLC (NASDAQ: VVPR ) +57%  on 1H results . More news on: VivoPower International PLC, Cocrystal Pharma, Inc., Mallinckrodt plc, Stocks on the move, , Read more ...

Spring Bank Pharmaceuticals (NASDAQ: SBPH )  jumps 20%  in premarket trading after announcing a clinical collaboration with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to explore the the co-administration of SB 11285, Spring Bank’s IV-administered Stimulator of Interferon G...

HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, R...

HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth...

Galmed Pharmaceuticals (NASDAQ: GLMD ) resumed with Overweight rating and $14 (142% upside) price target at Cantor Fitzgerald. More news on: Madrigal Pharmaceuticals, Inc., Xencor, Inc., Spring Bank Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Gainers: Lee Enterprises (NYSE: LEE )  +85% . More news on: Lee Enterprises, Incorporated, Roadrunner Transportation Systems, Inc., Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...